Compare Incyte Corporation (INCY) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Teladoc Health Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Teladoc Health Inc trades at $5.77 (market cap $1.01B). The key difference: Incyte Corporation is far larger — about 22.6× Teladoc Health Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Teladoc Health Inc for 39 Days on average.
| INCY | TDOC | |
|---|---|---|
Market Cap | $22.85B | $1.01B |
Volume | 1,927,029 | 4,668,477 |
Sector | Health | Health |
52-Week High | $129.93 | $9.72 |
52-Week Low | $83.80 | $4.47 |
Typical Hold Time | 33 Days | 39 Days |
Enterprise Value | $18.35B | $1.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
TDOC trades at $5.54, down 0.36% on the day, with a bearish technical signal and mixed earnings history. The company reported revenue of $2.53B in 2025 but a net loss of $200.32M, reflecting ongoing profitability challenges. Analyst consensus is a 'Hold' with a $8.83 price target, indicating potential upside. Recent news includes a CFO transition and legal investigations, adding to investor uncertainty.
The outlook remains cautious due to persistent losses and competitive pressures, though valuation metrics like P/S of 0.4 and EV/EBITDA of 5.89 suggest the stock is undervalued. Key risks include weak cash flow trends and BetterHelp segment volatility. Upside depends on execution in integrated care and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
